Study to compare efficacy and safety of masitinib at 6 mg/kg/day toplacebo in treatment of patients with Systemic mastocytosis with severe handicap

Phase 1

• Conditions: Smouldering Systemic or Indolent Systemic Mastocytosis with handicaps; MedDRA version: 18.0Level: PTClassification code 10026891Term: MastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disorders; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2008-000972-25-AT
• Lead Sponsor: AB Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-03
• Study Completion: 2015-11-02
• Last Update Posted: 2 August 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 223

Inclusion Criteria

1. Patient with one of the following documented mastocytosis as per WHO classification:
Smouldering Systemic Mastocytosis
Indolent Systemic Mastocytosis
2. Patient with documented mastocytosis and evaluable disease based upon histological criteria: typical
infiltrates of mast cells in a multifocal or diffuse pattern in skin and/or bone marrow biopsy
3. Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy
used at optimized dose (refer to table 2):
Anti H1
Anti H2
Proton pump inhibitor
Osteoclast inhibitor
Cromoglycate Sodium
Antileukotriene
4. Handicapped status defined as at least two of the following handicaps, including at least one among pruritus,
flushes, depression and fatigue:
Pruritus score = 9
Number of flushes per week = 8
Hamilton rating scale for depression(HAMD-17) score = 19
Number of stools per day = 4
Number of micturition per day = 8
Fatigue Impact Scale total score (asthenia) = 75
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 75
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 75

Exclusion Criteria

1. Patient with one of the following mastocytosis:
Cutaneous Mastocytosis
Not documented Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis
Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SMAHNMD)
Mast cell leukaemia (MCL)
Aggressive systemic mastocytosis (ASM)
2. Previous treatment with any Tyrosine Kinase Inhibitor

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified